Učitavanje...

Critical appraisal of bevacizumab in the treatment of ovarian cancer

Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Drug Des Devel Ther
Glavni autori: Yoshida, Hiroyuki, Yabuno, Akira, Fujiwara, Keiichi
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4423500/
https://ncbi.nlm.nih.gov/pubmed/25960638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S83275
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!